Olalekan Oluwole Archives
Oct. 25, 2017—Vanderbilt-Ingram Cancer Center (VICC) has been selected as one of the few authorized treatment centers in the United States approved to administer the first FDA- approved chimeric antigen receptor T cell (CAR T) therapy for treatment of adult patients with a specific type of lymphoma. VICC is the only cancer center in a seven-state region of the Southeast authorized to deliver the new immunotherapy.
Mar. 3, 2016—For the first time, Vanderbilt-Ingram Cancer Center (VICC) investigators have used a cancer patient’s own re-engineered immune cells to treat a form of blood cancer by stimulating the immune system.